# 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

> **NCT06630260** · PHASE1,PHASE2 · RECRUITING · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 182 (estimated)

## Conditions studied

- Glioblastoma Multiforme (GBM)
- Glioblastoma Multiform (Grade IV Astrocytoma)
- Diffuse Hemispheric Glioma, H3 G34-Mutant
- Malignant Primary Gliomas

## Interventions

- **DRUG:** Avutometinib
- **DRUG:** Defactinib
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT06630260
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2029-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630260, "5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT06630260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*